Complete skin remission of Sneddon‐Wilkinson disease with acalabrutinib
Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
Authors
- Henry Miles Prince (ORCID: https://orcid.org/0000-0002-0058-2448)
- Harmeet K. Bhullar (ORCID: https://orcid.org/0000-0001-6943-0250)
- Friyana Bhabha (ORCID: https://orcid.org/0000-0002-6067-4694)
- Christopher McCormack (ORCID: https://orcid.org/0000-0003-2549-0475)
Institutions
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1111/ajd.14386
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.44